Clinical trials
Immunotherapy clinical trials
Below are recruiting immunotherapy clinical trials, each written for real people, not researchers. We’re tracking 747 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06777628Recruiting
Blood test study to predict immunotherapy success in liver cancer
This study looks at blood cells from people with liver cancer (HCC) to see if we can predict early whether immunotherapy will work for them. It's a research study that involves blood tests during your normal care.
Bologna, Laura GramantieriAges 18 years+ - NCT06788366Recruiting
AI tool to predict outcomes in metastatic lung cancer
This trial is testing whether artificial intelligence can help predict how well people with advanced non-small cell lung cancer (NSCLC) respond to immunotherapy or chemo-immunotherapy. If you have stage IV NSCLC and have started this treatment, your data may help build a better prediction tool.
MilanAges 18 years+ - NCT07463248RecruitingPhase 2
PULSAR with Fecal Transplant for Advanced Liver Cancer
This trial tests a new combination treatment (PULSAR plus fecal microbiota transplant) for people with advanced liver cancer that stopped responding to initial therapy. It aims to see if this approach can help control the cancer again.
Chengdu, SichuanAges 18–75 - NCT06790797Recruiting
Predicting immunotherapy success in chest cancers
This study is for people with lung or esophageal cancer who will receive immunotherapy (drugs that help your immune system fight cancer). The researchers want to find markers in your blood and tumor that can predict how well the treatment will work.
Suzhou, JiangsuAges 18–80 - NCT07456358Recruiting
Immune attack targets in brain disease
This study looks at the immune system's role in neurological problems caused by cancer immunotherapy or autoimmune diseases. Researchers will collect spinal fluid to find out which immune targets are involved, which may help improve diagnosis and treatment.
Le Kremlin-BicêtreAges 18 years+ - NCT07458529RecruitingPhase 2
Chemoradiation plus immunotherapy with or without probiotics for rectal cancer
This trial tests adding an immunotherapy drug (tislelizumab) and a probiotic to standard chemoradiation for locally advanced rectal cancer that has not spread. The goal is to see if the probiotic helps the treatment work better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07457346RecruitingPhase 2
Testing emactinib with chemo and immunotherapy before head and neck cancer surgery
This trial tests whether combining the drug emactinib with chemotherapy and immunotherapy before surgery helps treat advanced head and neck cancer. It aims to shrink tumors and make surgery more effective.
Hangzhou, ZhejiangAges 18–75 - NCT06778213RecruitingPhase 4
Allergy shots for dust mite allergies tested in a special room
This trial tests if allergy shots (allergen-specific immunotherapy) can reduce symptoms of moderate to severe dust mite allergy. You will be in a room that exposes you to dust mites to see how well the treatment works, compared to a placebo.
Wroclaw, DLAges 18–65 - NCT06796517Recruiting
Immunotherapy for relapsed or refractory lymphoma
This trial tests immunotherapy for people with certain types of lymphoma (diffuse large B cell, primary mediastinal, high grade, or Burkitt) that came back or didn't respond to previous treatment. It aims to see if a new immune-based approach can help.
SeoulAges 19–74 - NCT05937438RecruitingPhase 1/Phase 2
Radiation then immunotherapy after esophagus surgery
This trial studies giving radiation right after esophagus surgery, followed by immunotherapy, to keep the cancer from coming back. It is for people with a specific type and stage of esophageal squamous cell carcinoma.
Hefei, AnhuiAges 18–75 - NCT07447869RecruitingEarly Phase 1
Lymph Node Exam in Cat Allergy Treatment Study
This study looks at lymph nodes in the neck to understand how the body responds to cat allergy treatments. It may help researchers improve allergy shots or other therapies for people with cat allergies.
Boston, MassachusettsAges 18–45 - NCT07452601RecruitingPhase 2
Timing of immunotherapy infusion in chemo before surgery for esophageal cancer
This trial tests whether giving immunotherapy and chemotherapy at a specific time of day improves outcomes for people with esophageal cancer before surgery. It may help shrink the tumor and make surgery more effective.
Xi'an, ShannxiAges 18–75 - NCT07452380Recruiting
Dust mite allergy shot therapy for kids with rhinitis or asthma
This trial tests allergy shots for children with dust mite allergies causing rhinitis or asthma. It aims to see if guiding treatment with detailed allergy testing leads to better results.
Hangzhou, ZhejiangAges 5–18 - NCT07453342Recruiting
Safety of immunotherapy side effects and restarting treatment
This study looks at patients who had side effects from cancer immunotherapy (checkpoint inhibitors). The goal is to understand those side effects and whether it is safe to restart immunotherapy after they resolve.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07448077RecruitingPhase 2
Short radiation with immunotherapy for rectal cancer
This trial tests a combination of short-course radiation, chemotherapy, and an immunotherapy drug (Enlonstobart) for patients with a specific type of rectal cancer called pMMR. It aims to see if this approach can shrink tumors before surgery and improve outcomes.
Shijiazhuang, HebeiAges 18 years+ - NCT06807307Recruiting
Using genetic tests to predict immunotherapy response in lung cancer
This study looks at genetic material from tumor samples to find patterns that can predict whether immunotherapy will work for people with advanced non-small cell lung cancer (NSCLC). The goal is to improve how doctors choose treatments for each patient.
RomeAges 18 years+ - NCT06806579Recruiting
Immunotherapy for advanced liver cancer
This trial studies how well immunotherapy drugs (atezolizumab and bevacizumab) work for people with advanced liver cancer that cannot be treated with local procedures. It looks at real-life results to see if these treatments help people live longer and feel better.
Torrette, ANAges 18 years+ - NCT04886401Recruiting
Study predicting response to pembrolizumab in advanced lung cancer
This study looks back at prior treatment to learn which patients with advanced non-small cell lung cancer (NSCLC) are more likely to respond to pembrolizumab, an immune therapy given up front. The results may help doctors better predict who benefits from this treatment.
BrestAges Any age - NCT06718257Recruiting
Chemo with immunotherapy and targeted drugs for bile duct cancer
This trial tests whether adding immunotherapy and targeted therapy to standard chemotherapy can help treat intrahepatic cholangiocarcinoma (a type of bile duct cancer). It is for patients who are starting treatment with one of two specific chemo regimens, possibly combined with the new drugs.
Hangzhou, ZhejiangAges 18 years+ - NCT07427186Recruiting
Studying how immunotherapy affects the immune system in early-stage cancer
This trial looks at how your immune system responds to immunotherapy given before surgery for early-stage solid tumors (like lung, head and neck, melanoma, or bladder cancer). The goal is to understand why some people respond better, so doctors can improve treatment for future patients.
ToulouseAges 18 years+ - NCT07434284RecruitingEarly Phase 1
Cell therapy plus immunotherapy for advanced gynecologic cancers
This trial is testing a new combination treatment for advanced gynecologic cancers (like ovarian, cervical, or endometrial) that have not responded to standard therapies. It combines a type of cell therapy (cCTL) with another immunotherapy to see if it can help patients who have few other options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07431073RecruitingPhase 2
Immunotherapy master trial for advanced cancers
This trial tests different immunotherapy treatments for people with advanced cancer that has spread or cannot be removed by surgery. It aims to find out which treatments work best by studying your tumor and blood samples over time.
VillejuifAges 12 years+ - NCT06714708RecruitingPhase 2
Low-dose radiation with immunotherapy and chemo before surgery for lung cancer
This trial tests a combination of low-dose radiation, an immunotherapy drug called sintilimab, and standard chemotherapy before surgery for stage II–III non-small cell lung cancer (NSCLC). The goal is to see if this approach can shrink tumors and improve outcomes for patients who are candidates for surgery.
Hefei, AnhuiAges 18 years+ - NCT07422779Recruiting
Immunotherapy for advanced melanoma study
This study tests how well immunotherapy drugs like pembrolizumab and nivolumab work for people with advanced melanoma that has spread. It aims to find markers that predict treatment response.
LjubljanaAges 18 years+
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunotherapy?
- Yes. Clin2 currently lists 747 recruiting immunotherapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunotherapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunotherapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.